12th November, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 545012

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Symbol: ENNATURE

Dear Sirs,

Sub: Outcome of the Board Meeting held on 12th November, 2026

Further to our letter dated 5th November, 2026 and pursuant to Regulation 30 and Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e. 12th November, 2026 has, inter-alia, considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.

A copy of Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 along with the Limited Review Report of Statutory Auditors thereon are enclosed herewith.

The above said Board Meeting commenced at 12:19 Hrs. and concluded at 13:35 Hrs.

This is for your information and record.

Thanking you,

Yours truly,
For Ennature Bio Pharma Limited

PREETI CHOUDHARY

Digitally signed by PREETI CHOUDHARY
DN: c=IN, o=Personal, postalCode=201010, st=GHAZIABAD, st=UTTAR PRADESH, street=W/O MOHIT PATEL HOUSE NUMBER--UGM-66 AGNARA LANENAME PLOT NUMBER-16 SECTOR-4 VASHALI,E.SAHIBABAD, 2.5.4.20=8255198eed54414729631102e9e0d934 55bb805c4e39951f844e739a8f7dd1e6, serialNumber=6da6f6f5d594716c5d074675c513 f0da222ef78b27ac86cc1fc1398bd4f402a49c, email=pm9.08@gmail.com, cn=PREETI CHOUDHARY
Date: 2026.11.12 13:36:50 +05'30'

Preeti Choudhary
Company Secretary & Compliance Officer
Encl: A/a

ENNATURE
BIOPHARMA

ENNATURE BIO PHARMA LIMITED

Regd. Office ; P.No.4, Pharma City, Selaqui-248197, Dehradun (Uttarakhand)
Phones: +91 135 2698620, Fax: +91 135 2698939
Email: compliance.officer@ennature.com, Website: www.ennaturebiopharma.com
CIN No.U24290UR2021PLC013005

Statement Of Unaudited Financial Results for the Quarter and Half year ended September 30, 2026

(₹ In Lakhs, except as stated)

S.No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Unaudited)
1	**Income from operations**						
	(a) Revenue from operations	7,845.87	9,039.42	5,414.14	16,885.29	11,277.62	24,615.42
	(b) Other income	-	-	-	-	-	-
	Total income	7,845.87	9,039.42	5,414.14	16,885.29	11,277.62	24,615.42
2	**Expenses**						
	(a) Cost of materials consumed	3,109.05	6,078.80	2,850.10	9,187.85	6,810.01	13,077.20
	(b) Changes in inventories of finished goods, Stock-in Trade and work-in-progress	1,377.06	(489.61)	326.16	887.45	116.81	1,732.66
	(c) Employee benefits expense	746.18	591.06	600.21	1,337.24	1,159.85	2,352.57
	(d) Finance Costs	2.50	3.71	378.85	6.21	591.63	1,286.03
	(e) Depreciation and amortisation expense	370.08	370.20	361.05	740.28	722.10	1,446.70
	(f) Power and fuel	453.45	452.94	276.14	906.39	562.02	1,240.72
	(g) Other Expenses	1,126.40	1,407.93	757.67	2,534.33	1,512.08	3,294.82
	Total Expenses	7,184.72	8,415.03	5,550.18	15,599.75	11,474.50	24,430.70
	Profit Before Interest, Depreciation and Tax (EBIDTA)	1,033.73	998.30	603.86	2,032.03	1,116.85	2,917.45
3	**Profit / (Loss) from operations before exceptional items and tax (1-2)**	**661.15**	**624.39**	**(136.04)**	**1,285.54**	**(196.88)**	**184.72**
4	Exceptional Items	-	-	-	-	-	28.00
5	**Profit / (Loss) before Tax (3-4)**	**661.15**	**624.39**	**(136.04)**	**1,285.54**	**(196.88)**	**156.72**
6	Tax expense :						
	(a) Current Tax	81.78	80.71	-	162.49	-	-
	(b) Deferred Tax	90.69	77.72	(7.85)	168.41	(22.60)	35.90
7	**Profit / (Loss) for the period (5-6)**	**488.68**	**465.96**	**(128.19)**	**954.64**	**(174.28)**	**120.82**
8	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or Loss	(3.69)	(3.69)	(8.50)	(7.38)	(17.00)	(34.00)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	0.93	0.93	2.00	1.86	4.00	8.00
	B (i) Items that will be reclassified to Profit or Loss	-	-	-			-
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-			-
	Other Comprehensive Income (Net of Tax)	**(2.76)**	**(2.76)**	**(6.50)**	**(5.52)**	**(13.00)**	**(26.00)**
9	**Total comprehensive income / (loss) for the period (7+8)**	**485.92**	**463.20**	**(134.69)**	**949.12**	**(187.28)**	**94.82**
10	Paid-up Equity Share Capital (Face value Rs. 5/- each)	1,117.11	1,117.11	1,117.11	1,117.11	1,117.11	1,117.11
11	Other Equity						51,172.28
12	**Earning per equity share (face value of Rs 5/- each) Not annualised (In Rs.)**						
	- Basic	2.19	2.09	(0.57)	4.27	(0.78)	0.54
	- Diluted	2.19	2.09	(0.57)	4.27	(0.78)	0.54

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

Ennature Bio Pharma Limited

Notes:

1 The above financial results have been prepared in accordance with the recognition and measurement principles of accounting standards generally accepted in India, including the Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 .

2 The above financial results have been reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective meetings held on November 12, 2026. These financial results have been limited reviewed by the statutory auditors of the company.

3 The Board of Directors of the Ennature Bio Pharma Limited at its meeting held on May 16, 2025 had approved the Scheme of Arrangement ("The Scheme") under sections 230-232 and other applicable provisions of the Companies Act, 2013 for demerger amongst India Glycols Limited {"IGL" or "the Demerged Company", IGL Spirits Limited ("the Resulting Company-1") and Ennature Bio Pharma Limited ("the Company" or the Resulting Company-2) for demerger of spirits & biofuel undertaking and biopharma undertaking on going concern basis from the Demerged Company into Resulting Company-1 and the Company respectively, which was approved by Honorable National Company Law Tribunal ("NCLT"), Allahabad Bench vide its order dated July 17, 2026 (formal order received on August 20, 2026). The said NCLT order was filed with the Registrar of Companies ("ROC") on September 01, 2026 thereby making the Scheme effective. In terms of the Scheme, all assets and liabilities of the spirits and biofuel undertaking of the Demerged Company were transferred and vested into the Company on April 01, 2026, being the Demerger Appointed Date.
Consequently, the company has given accounting effect of the Scheme in the above results in accordance with the accounting treatment prescribed under the Scheme and Appendix C of Ind AS 103-"Business combination of entities under common control". Accordingly, the comparative financial results and other financial information for the quarters/year included in this statement have also been restated make figure for comparable.
The figures for the comparative periods are not audited/reviewed by the Statutory Auditors. Further, restatement of financial figures for the year ended March 31, 2026 has been done based on audited financial results of the Demerged Company which has not been separately subject to audit or review.
The book values of the assets and liabilities transferred to and vested in the Company, and the related income and expenses, have been extracted from the audited financial statements of the Demerged Company, which have not been separately subjected to audit or review.

4 The paid up capital has been issued as per the Scheme but comparative figures, the figure of paid up capital has been stated to make the statement comparable.

5 As the Company's business activity falls within a single primary business segment, namely Ennature Biopharma, the disclosure requirements as per nd-AS 108 "operating segments" are not applicable.

6 The Company has identified its business operations as a single reportable segment, namely 'Ennature Biopharma', in accordance with the requirements of Ind AS 108 – Operating Segments. Accordingly, no separate segment information has been provided for the current period.

7 The figures for corresponding previous period have been re-grouped/re-classified whereever necessary to make them comparable with the current period figures.

For ENNATURE BIO PHARMA LIMITED

Ennature Bio Pharma Limited

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

PRAGYA BHARTIA BARWALE
Managing Director
DIN: 02109262

Place : Noida
Date : 12th November , 2026

Statement of Cash Flows

(₹ In Lakhs)

	Particulars	Half Year ended 30.09.2026 (Unaudited)	Half Year ended 30.09.2025 (Unaudited)
A.	**Cash Flow from Operating Activities**		
	Net Profit/(Loss) Before Tax	**1,285.54**	**(196.88)**
	Adjustments For:		
	Depreciation and amortisation expense	740.28	722.10
	(Profit)/Loss on Sale of Property, plant & equipment	0.38	-
	Provision No Longer Required Written Back	4.55	-
	Finance Costs	6.21	591.63
	Operating Profit/ (Loss) before Working Capital Changes	**2,036.96**	**1,116.85**
	Adjustments For:		
	(Increase)/Decrease in Trade & Other Receivables	(2,534.57)	4,190.69
	(Increase)/Decrease in Inventories	1,299.75	(181.57)
	Increase / (Decrease) in Trade & Other Payables	544.17	(1,091.21)
	Cash Generated from / (Used in) Operations	**1,346.31**	**4,034.76**
	Income Tax Paid (Net)	(91.81)	-
	Net Cash flow from / (Used in) Operating Activities	**1,254.50**	**4,034.76**
B.	**Cash Flow from Investing Activities**		
	Purchase of Property, plant & equipment	(415.18)	(714.19)
	Sale of Property, plant & equipment	0.02	79.44
	Net Cash flow from / (Used in) Investing Activities	**(415.16)**	**(634.75)**
C.	**Cash Flow from Financing Activities**		
	Repayment of Borrowings	(825.62)	(2,802.80)
	Finance Costs Paid	(6.21)	(591.63)
	Net Cash flow from / (Used in) Financing Activities	**(831.83)**	**(3,394.43)**
	Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C]	**7.51**	**5.58**
	Opening Cash & Cash Equivalents	**24.30**	**15.13**
	Closing Cash & Cash Equivalents	**31.81**	**20.71**

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard -7, "Statement of Cash Flows".

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

Emnature Bio Pharma Limited

Statement of Assets and Liabilities

(₹ In Lakhs)

	Particulars	As At 30.09.2026 (Unaudited)	As At 31.03.2026 (Unaudited)
A.	**ASSETS**		
1	**Non-current Assets**		
	(a) Property, Plant and Equipment	53,678.56	54,412.76
	(b) Capital work-in-progress	1,069.96	656.55
	(c) Other Intangible assets	49.26	53.97
	(d) Financial Assets		
	(i) Loans	0.35	2.39
	(ii) Others	194.15	194.15
	(e) Other non-current assets	3.62	21.00
	Total Non Current Assets	54,995.90	55,340.82
2	**Current Assets**		
	(a) Inventories	6,742.55	8,042.30
	(b) Financial Assets		
	(i) Trade receivables	5,005.25	5,437.69
	(ii) Cash and cash equivalents	31.81	24.30
	(iii) Others	3,152.23	181.73
	(c) Other current assets	579.70	563.77
	Total Current Assets	15,511.54	14,249.79
	Total Assets	**70,507.44**	**69,590.61**
B.	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	1,117.11	1,117.11
	(b) Other Equity	52,120.89	51,172.28
	Total Equity	53,238.00	52,289.39
2	**Liabilities**		
2.1	**Non-current Liabilities**		
	(a) Financial Liabilities		
	(i) Other financial liabilities	14.07	16.66
	(b) Provisions	94.56	95.63
	(c) Deferred tax liabilities (Net)	6,353.03	6,184.62
	(d) Others	271.95	271.95
	Total Non-current Liabilities	6,733.61	6,568.86
2.2	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	-	825.62
	(ii) Trade payables		
	total outstanding dues of micro enterprises and small enterprises	16.61	16.61
	total outstanding dues of creditors other than micro enterprises and small enterprises	9,505.30	9,047.35
	(iii) Other financial liabilities	385.40	393.64
	(b) Other current liabilities	352.48	331.87
	(c) Provisions	124.65	117.27
	(d) Current Tax Liabilities (Net)	151.39	-
	Total Current Liabilities	10,535.83	10,732.36
	Total Equity and Liabilities	70,507.44	69,590.61

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

Emmature Bio Pharma Limited

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Ennature Bio Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Ennature Bio Pharma Limited ('the Company') for the quarter ended 30 September 2026 and the year-to-date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to note 3 to the Statement with respect to the Scheme of Arrangement ("Scheme") duly approved by the Hon'ble NCLT, which became effective on September 1, 2026, upon it being filed with the Registrar of Companies, Uttarakhand. The demerger of Biopharma undertaking of India Glycols Limited and its vesting in the Company has been approved w.e.f. April 1, 2026 (the

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE,
NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

appointed date as per the scheme). The Company has accounted for vesting of Biopharma undertaking in accordance with the Pooling of Interest method as laid down in Appendix C of Ind AS 103 "Business Combinations" and as specified in the Scheme. The figures of the comparative periods have been restated as to make the figures comparable. Our conclusion is not modified in respect of this matter.

6. The financial information for the corresponding quarter and half year ended September 30, 2025 and year ended March 31, 2026, as reported and included in these unaudited financial results, have been extracted by the Management from the financial information of India Glycols Limited pertaining to Biopharma Undertaking for the period from April 01, 2025 to March 31, 2026. As set out in Note 3 to the unaudited financial results, these figures have been furnished by the Management, and we have neither reviewed nor audited these figures.

   Our report on the statement is not modified in respect of this matter.

For **K N Gutgutia & Co.**
Chartered Accountants
Firm Registration No: 304153E

B. R. Goyal
Partner
Membership No. 012172
UDIN:26012172FHEXJE6583

Place: New Delhi
Date: 12th November 2026